Gut Microbiomes in HD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-30

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease. The investigators are trying to determine if patients who are diagnosed with adult-onset HD and who exhibit a rapid rate of disease progression have unique populations of bacteria in their gut as compared to patients with slower progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain-Gut-Microbiota Interaction in IBS

NCT04296552

Irritable Bowel Syndrome Functional Gastrointestinal Disorders

UNKNOWN NA

Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease

NCT06215222

IBS - Irritable Bowel Syndrome Healthy Functional Bloating +1 more

RECRUITING

Small Intestinal Bacterial Overgrowth: A Prospective Registry

NCT01822470

Functional Dyspepsia Small Intestinal Bacterial Overgrowth

ENROLLING_BY_INVITATION

Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment

NCT06066866

Healthy IBS - Irritable Bowel Syndrome Inflammatory Bowel Diseases

NOT_YET_RECRUITING

Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome

NCT02681666

Abdominal Pain Irritable Bowel Syndrome IBS

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Two of the most common non-neurological features of Huntington disease (HD) are progressive weight loss and metabolic dysfunction. However, a small proportion of HD patients are pathologically overweight, despite having similar CAG repeat lengths as pathologically underweight patients. The investigators hypothesize this spectrum of weight abnormalities may be caused by HD-related metabolic dysfunction.

Pathological weight loss is recapitulated in transgenic HD model mice expressing fragments of human huntingtin (HTT), either transgenically3,4 or knocked-in to a portion of the mouse HD homolog (Hdh) gene5. Conversely, pathological weight gain is recapitulated in transgenic HD model mice expressing full-length human HTT either along with the full complement of Hdh6,7 or in Hdh-null backgrounds8,9.

In Hdh-null background transgenic HD model mice, which are pathologically overweight, circadian feeding is disrupted, despite maintenance of naturally nocturnal circadian activity. Interestingly, circadian feeding patterns are restored by suppression of brain HTT (unpublished Dr. Amber Southwell), suggesting that HTT plays a role in circadian feeding regulation. Furthermore, when circadian feeding patterns are artificially restored with scheduled feeding, striatal HTT is temporarily suppressed, while metabolic markers and body weight are normalized (unpublished Dr. Amber Southwell). Together, this demonstrates that HTT is involved in gut-brain feedback, but since HTT suppression during scheduled feedings is transient, while metabolic effects are lasting, HTT is likely not the master regulator of this feedback loop. Instead, the gut microbiome may influence this pathway, possibly contributing to the onset and/or progression of HD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Patients who are not diagnosed with HD

No interventions assigned to this group

Experimental Group 1

Underweight HD patients

No interventions assigned to this group

Experimental Group 2

Overweight HD patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Provide informed consent
* Able to read and speak English
* Agree to comply with study procedures

* CAG repeat length ≤ 26.
* BMI 18.5-24.9

* BMI \< 18.5 (underweight) or significant, involuntary weight loss within the past 12 months.
* CAG repeat length 40 - 59.
* Documentation of the Clinical Diagnosis of HD with a high level of certainty (\>99% confidence) using the validated Unified Huntington's Disease Rating Scale (UHDRS).
* Stage I-III on the Functional Assessment component of the UHDRS

* BMI \> 25.0 (overweight - obesity) or BMI ≤ 25.0 with significant, unexplained weight gain within the past 12 months
* CAG repeat length 40 - 59.
* Documentation of the Clinical Diagnosis of HD with a high level of certainty (\>99% confidence) using the validated UHDRS.
* Stage I-III on the Functional Assessment component of the UHDRS

Exclusion Criteria

* CAG repeat length ≥ 60 to exclude participants with juvenile onset HD.
* CAG repeat length 36 - 39 to exclude participants with reduced penetrance. As this is a pilot study, we are primarily interested in participants with typical HD characteristics.
* UHDRS Functional Capacity stage ≥ 4 to exclude late-stage HD patients who may be institutionalized and receive nutrition through a feeding tube.
* Use of any of the following drugs within the last 6 months:

* System antibiotics, antifungals, antivirals, or anti-parasitics (intravenous, intramuscular, or oral)
* Corticosteroids (intravenous, intramuscular, oral, nasal, or inhaled)
* Cytokines
* Methotrexate, immunosuppressive cytotoxic agents, or chemotherapy
* Commercial probiotics ≥ 100 million CFU (fermented foods, yogurts, and other homeopathic probiotics and prebiotics do not apply)
* Use of topical antibiotics or topical steroids within the last 7 days
* History of active, uncontrolled gastrointestinal disorders or diseases, including:

* Inflammatory bowel disease
* Ulcerative colitis
* Crohn's disease
* Irritable bowel syndrome
* Infectious gastroenteritis, colitis, or gastritis
* Clostridium difficile or Helicobacter pylori infection
* Persistent or chronic constipation or diarrhea
* Acute illness with or without fever at time of sample collection
* Positive for HIV, hepatitis B, or hepatitis C
* Confirmed or suspected immunodeficient condition/state
* Major surgery of the GI tract, excluding cholecystectomy and appendectomy
* Unstable dietary history within the past month, such as elimination or significant increase of a major food group in the diet
* Recent history of chronic, excessive alcohol consumption
* Travel outside of the United States within the last 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes